Ascendis Pharma (ASND) CLO discloses warrants and RSU holdings in Form 3

Rhea-AI Filing Summary

Ascendis Pharma A/S executive Michael Wolff Jensen has filed a Form 3 detailing his equity-based holdings in the company. As EVP and Chief Legal Officer, he reports fully vested, currently exercisable warrants over 30,000 ordinary shares at an exercise price of 62.1700 per share, additional warrants over 27,000 shares at 108.0000, 22,755 shares at 176.2800, and 14,504 shares at 139.6500, all held directly.

He also reports restricted stock units representing 4,246, 3,197 and 9,552 ordinary shares. According to the footnotes, one RSU grant vests on March 1, 2027 with no expiration date, while other grants vest in two or three equal annual installments beginning on March 1, 2027. Each restricted stock unit corresponds to a contingent right to receive one ADS.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

JENSEN MICHAEL WOLFF

(Last) (First) (Middle)

C/O ASCENDIS PHARMA A/S

TUBORG BOULEVARD 12

(Street)

HELLERUP DK-2900

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Ascendis Pharma A/S [ ASND ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Legal Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	(1)	12/11/2028	Ordinary Shares	30,000	$62.17	D
Warrants	(1)	12/10/2029	Ordinary Shares	27,000	$108	D
Warrants	(1)	12/10/2030	Ordinary Shares	22,755	$176.28	D
Warrants	(1)	12/09/2031	Ordinary Shares	14,504	$139.65	D
Restricted Stock Units	(2)	(2)	Ordinary Shares	4,246	(3)	D
Restricted Stock Units	(4)	(4)	Ordinary Shares	3,197	(3)	D
Restricted Stock Units	(5)	(5)	Ordinary Shares	9,552	(3)	D

Explanation of Responses:

1. The warrants are fully vested and currently exercisable.

2. The restricted stock units vest on March 1, 2027 and have no expiration date.

3. Each restricted stock unit represents a contingent right to receive one ADS.

4. The restricted stock units vest in two equal annual installments beginning on March 1, 2027.

5. The restricted stock units vest in three equal annual installments beginning on March 1, 2027.

	/s/ Michael Wolff Jensen	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Ascendis Pharma (ASND) executive Michael Wolff Jensen report in this Form 3?

He reports his initial beneficial ownership of equity awards in Ascendis Pharma A/S. The filing lists multiple series of fully vested warrants and several restricted stock unit grants, all held directly, giving transparency into his derivative-based exposure to the company’s ordinary shares.

How many Ascendis Pharma (ASND) shares are covered by Michael Wolff Jensen’s reported warrants?

He reports warrants linked to 30,000, 27,000, 22,755 and 14,504 ordinary shares. Each warrant block has its own exercise price and expiration date, and the footnotes state that these warrants are fully vested and currently exercisable, reflecting established option-like positions.

What restricted stock units does Michael Wolff Jensen hold in Ascendis Pharma (ASND)?

He holds RSUs representing 4,246, 3,197 and 9,552 ordinary shares. The RSUs vest either entirely on March 1, 2027 or in two or three equal annual installments starting that date, and each RSU corresponds to a contingent right to receive one ADS.

Are Michael Wolff Jensen’s Ascendis Pharma (ASND) warrants currently exercisable?

Yes. The footnotes clarify that the reported warrants are fully vested and currently exercisable. They cover ordinary shares at exercise prices of 62.1700, 108.0000, 176.2800 and 139.6500 per share, each with its own specified expiration date in 2028, 2029, 2030 and 2031.

When do Michael Wolff Jensen’s Ascendis Pharma (ASND) RSUs vest?

One RSU grant vests on March 1, 2027 with no expiration date. Other RSU awards vest in two or three equal annual installments beginning on March 1, 2027, meaning portions convert to ADS-linked rights over successive years after that start date.

What security underlies Michael Wolff Jensen’s RSUs and warrants in Ascendis Pharma (ASND)?

Both the warrants and RSUs are tied to Ascendis Pharma’s ordinary shares. The filing notes that each restricted stock unit represents a contingent right to receive one ADS, while each warrant provides a right to acquire ordinary shares at a stated exercise price before expiration.